Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Velocity Pharmaceutical Development Announces Clinical Development Agreement

SOUTH SAN FRANCISCO, Jan. 15, 2013 /PRNewswire/ -- Velocity Pharmaceutical Development LLC (VPD) today announced the signing of a Licensing Agreement to pursue a drug development program utilizing EuMederis Pharmaceuticals' EuPort technology for optimizing the pharmaceutical properties of peptide drugs.  Research and further development is being funded and carried out through a special purpose development company, Spitfire Pharma, Inc., operating largely in virtual mode. The program will be managed by members of the Velocity Pharmaceutical Development team and by John Nestor, Ph.D., CEO of EuMederis.

Peptide hormones control a host of critical functions throughout the body. Peptide drugs, however, typically have a short duration of action and require self-injection thus limiting their utility. Recent advances in the design, synthesis and delivery of peptides, such as the EuPort technology, have increased interest in this attractive pharmaceutical class.

"The EuMederis model of rapid peptide optimization has quickly provided us with an attractive peptide development candidate and its low-infrastructure organization is consistent with our plan for Velocity Pharmaceutical Development," explained David J. Collier, M.D., CEO of Velocity Pharmaceutical Development LLC.

"We expect that the Velocity model for rapid and focused clinical development programs in relatively flat organizations will find many adherents in the future of biopharmaceutical development," said John Nestor, Ph.D., founding CEO, EuMederis Pharmaceuticals, Inc. "It is a pleasure to be working with such a highly experienced team of drug development experts."

The deal terms and therapeutic target are unannounced at this time.

About Velocity Pharmaceutical Development, LLC

Velocity Pharmaceutical Development (VPD) is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model.  VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated.  VPD then manages a highly virtual development program for each drug candidate intended to generate convincing human proof of concept data.   Following successful human proof of concept, VPD then seeks a large pharmaceutical company acquirer for each program.  VPD is staffed by a seasoned team of clinical drug developers with expertise in identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials. This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures. VPD operates on a rapid decision principle, which identifies drug candidates with the greatest promise and repurposes capital from those that don't work out early in the process. VPD believes this new capital-efficient model will yield attractive new drugs to treat patients with significant unmet clinical needs. The company is located in South San Francisco, California.  More information is available at www.vpd.net.

About EuMederis Pharmaceuticals, Inc.

EuMederis Pharmaceuticals, Inc. (www.eumederis.com) is a seed-stage biotechnology company focused on the design and development of Best-in-Class peptide therapeutics with optimized pharmaceutical properties. EuMederis' EuPort technology utilizes a proprietary chemical modification to increase the duration of action and bioavailability of peptides, generating optimized new chemical entities. EuMederis is led by John J. Nestor, Jr., Ph.D., who has more than 35 years of experience in peptide hormone design and development, both in major pharmaceutical companies (Syntex, Roche Bioscience) and in San Diego biotech companies (Sequenom, Inc.; TheraPei Pharmaceuticals, Inc.). He is lead inventor of pharmaceuticals marketed by Roche (Valcyte®), Merck/Organon (Orgalutran®) and Pfizer/Searle (Synarel®). The company is located in San Diego, California.

Contact 
Leslie Loven
1-415-524-7326
leslie@vpd.net

SOURCE Velocity Pharmaceutical Development, LLC

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
Is it just me, or has there been an explosion of buzz words lately? Don’t get me wrong, the IT industry innovates at a crazy pace normally, but it seems that things have been evolving faster than ever and that a fundamental change in the way things are done is underway. We can attribut...
My favorite writer, Gil Press, sums it up with, “It’s Official: The Internet Of Things Takes Over Big Data As The Most Hyped Technology” where he talks about how Gartner released its latest Hype Cycle for Emerging Technologies, and how big data has moved down the “trough of disillusion...
Earlier, I wrote a bit about traffic and the IoT. It's a big topic. The traffic problems of the developed and developing worlds seem so large, complex, and intractable to significant change in any reasonable timeframe. Consider Mexico City. There are more than 20 million people in ...
More and more Web sites and applications are being moved from Apache to nginx. While Apache is still the number one HTTP server with more than 60% on active Web sites, nginx has now taken over the 2nd place in the ranking and relegated Microsoft’s IIS to 3rd place. Among the top 10.000...
Getting one's arms around the Internet of Things is a daunting task. In addition to big IoT commitments from all of the big players in computing and telco, there are a number of smaller companies and startups working on devices and services to enable the future of enterprise IT and per...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE